One of the major challenges faced in defining clinically applicable and homogeneous molecular tumor subtypes is assigning biological and/or clinical interpretations to etiological (intrinsic) subtypes. The conventional approach involves at least three steps: Firstly, identify subtypes using unsupervised clustering of patient tumours with molecular (etiological) profiles; secondly associate the subtypes with clinical or phenotypic information (covariates) to infer some biological meaning to the redefined subtypes; and thirdly, identify clinically relevant biomarkers associated with the subtypes. Here, we report the implementation of a tool, phenotype mapping (phenMap), which combines these three steps to define functional subtypes with associated phenotypic information and molecular signatures. phenMap models meta (unobserved) variables as a function of covariates to expose any underlying clustering structure within the data and discover associations between subtypes and phenotypes. We demonstrate how this tool can more avidly identify functional subtypes that are an improvement over already existing etiological subtypes by analysing published breast cancer gene expression data.
Recent initiatives such as The Cancer Genome Atlas (TCGA) 8 and
International Cancer Genome Consortium (ICGC) 9 have lead to the generation of hitherto unprecedented levels of data on tumor genomics, metabolomics and phenomics. The conventional approach of tumor stratification involves unsupervised clustering approaches such as self-organizing maps (SOM) 10 , hierarchical clustering (HC) 11 , and non-negative matrix factorization (NMF) 3, 6, 12, 13 . This unsupervised clustering approach uses only single or multiomics profiles (as in iCluster 14, 15 
Results

Application of phenMap in cancer
The phenMap framework can be applied to uncover clustering structure underlying the expression data, discover associated phenotypes and Moreover, subtype-specific genes were further refined using prediction analysis of microarrays (PAM) analysis (dubbed as breast cancer G-Assigner "BrCa-G-Assigner" gene signature; Figures 2E) . We also applied our probabilistic version of principal component analysis with covariates (PPCCA) 18 and NMF 3, 6, 12, 13 
Discussion
Currently personalized approaches for diagnosis and treatment of many diseases including cancer require stratification of patients into sub-groups based on high-throughput molecular and phenotypic data. The conventional clustering approaches are employed to identify subtypes in omics data and later, phenotypes are associated with the subtypes as a post-clustering step.
In the past two decades, this approach to subtyping has led to identification of subtypes in multiple cancer types that are clinically not in practice. Statistical power to discover association between the new subtypes and phenotypes is reduced due to several steps involved in this conventional subtyping approach. There is need for a new generation of clustering methods that can simultaneously cluster and integrate both omics and phenotypic data to identify subtypes of clinical importance.
Here we introduce a new concept of "functional subtyping" that involves identification of subtypes associated with phenotypes (covariates) using
phenMap. This model can be applied to any continuous high-throughput omics data with matched covariates information to identify: i) subtypes, ii) covariates associated with the subtypes and iii) features driving the clustering. The application of this model in cancer is highlighted using a published omics data types (transcriptomics) with samples from breast cancer cell lines 17 . We compared the identified functional subtypes to already known and published breast cancer subtypes that were identified using the same data by conventional clustering approaches. This approach of functional subtyping offers the prospect of identifying robust and clinically important subtypes.
This model can also be extremely useful in other molecular datasets such as proteomics data. However, the current scope of phenMap model does not accommodate non-Gaussian data as profile data. Research on different link functions to allow phenMap to model count and categorical data is underway.
Methods
Datasets and samples
We used our already published gene expression microarray data for 36 breast cancer cell lines and four drug response (IC 50 ) data 17 . 
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